Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078629 | 1.00 | ALDH1A1 (0.48) | ALDH1A1UTS2RKDM4ETAAR1ALOX15 | |
| SCHEMBL5155646 | 0.85 | ALDH1A1 (0.58) | ALDH1A1UTS2RKDM4ETAAR1ALOX15 | |
| SCHEMBL8468699 | 0.83 | UTS2R (0.50) | ALDH1A1UTS2RLMNAMAPT | |
| SCHEMBL8466170 | 0.83 | UTS2R (0.50) | ALDH1A1UTS2RLMNAMAPT | |
| SCHEMBL29389604 | 0.82 | ALDH1A1 (0.63) | ALDH1A1UTS2RKDM4ETAAR1LMNA | |
| SCHEMBL82574 | 0.82 | ALDH1A1 (0.63) | ALDH1A1UTS2RKDM4ETAAR1LMNA | |
| SCHEMBL3752645 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KDM4ETAAR1ALOX15LMNA | |
| SCHEMBL226267 | 0.81 | ALDH1A1 (0.54) | ALDH1A1UTS2RKDM4ETAAR1ALOX15 | |
| SCHEMBL4087510 | 0.81 | ALDH1A1 (0.42) | ALDH1A1UTS2RKDM4ETAAR1ALOX15 | |
| SCHEMBL4091564 | 0.81 | ALDH1A1 (0.42) | ALDH1A1UTS2RKDM4ETAAR1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2060559-A1 | Process for the preparation of enantiomerically pure 3-hydroxy-3-arylpropylamines and their optical stereoisomers | Cadila Pharmaceuticals Limited (IN) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060559-A1 | Process for the preparation of enantiomerically pure 3-hydroxy-3-arylpropylamines and their optical stereoisomers | Cadila Pharmaceuticals Limited (IN) | 2009-05-20 | — | — | EP | disclosed |